TY - JOUR T1 - Silicone Induced Granuloma of Breast Implant Capsule (SIGBIC) diagnosis: Breast Magnetic Resonance (BMR) ability to detect silicone bleeding JF - medRxiv DO - 10.1101/2020.01.15.20017350 SP - 2020.01.15.20017350 AU - Eduardo de Faria Castro Fleury Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/20/2020.01.15.20017350.abstract N2 - Objective To evaluate the ability of BMRI to detect silicone gel bleeding in a prospective observational study including consecutive patients referred for BMRI scan. Methods: From January 2017 to March 2018, patients referred for BMRI were evaluated in a prospective observational study. Patients who had breast implants were included. BMRI recorded 9 findings according to BI-RADS lexicon and SIGBIC findings, considered equivocal features to detect gel bleeding (GB). Three new original imaging features were added for SIGBIC diagnosis: black drop signal; T2* hypersignal mass; and delayed contrast enhancement, considered as irrevocable signs. The presence of silicone corpuscle was confirmed by percutaneous biopsy or surgical capsulectomy. Accuracy of BMRI SIGBIC findings to predict GB was determined. We also used univariate analysis for the equivocal features for GB diagnosis. The Backward method was applied for a multivariate Logistic Regression model for the equivocal features. Results: SIGBIC was diagnosed in 208 patients and GB was histologically confirmed in all cases. No false positive results were observed. The most important imaging equivocal feature associated with GB was capsular contracture. In order of prevalence, the main equivocal BMRI features associated to GB with statistically significance (P < =0.001) were as follows: 1.water droplets (OR=2.8; 95%CI 1.8-4.4); 2.enlarged intramammary lymph node (OR=3.1; 95%CI 1.5-6.1); 3.pericapsular edema (OR=5.0; 95%CI 2.3-11.1); and 4.intracapsular seroma (OR=2.4; 95%CI 1.4-4.1).Conclusion SIGBIC diagnosis has high sensitivity to predict GB by the 3 irrevocable BMRI features described by the authors. We suppose GB is underdiagnosed in clinical practice by BI-RADS features.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPlataforma Brasil CAAE: 77215317.0.0000.0072Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data is available in authors files.SIGBICsilicone-induced granuloma of breast implant capsuleBMRIbreast magnetic resonance imagingGBgel bleedingBIA-ALCLbreast implant-associated anaplastic large cell lymphomaEILNenlarged intramammary lymph nodeSIISsilicone implant incompatibility syndrome ER -